- Approval Id
- 27897bb36ea4e15b
- Drug Approval Emc Name
- Amikacin 250 mg/ml Solution for Injection/Infusion
- Drug Name
- Amikacin 250 mg/ml Solution for Injection/Infusion
- Company Name
- Tillomed Laboratories Ltd
- Company Address
- 220 Butterfield, Great Marlings, Luton, LU2 8DL, UK
- Company Website
- http://www.tillomed.com/
- Company Telephone
- +44 (0)1480 402 400
- Company Medical Info Direct Line
- +44 (0)1480 402 400 [option 2]
- Company Medical Info Email
- Medical.Information@Tillomed.com
- Company Customer Care Direct Line
- +44 (0)1480 402 400 [option 1]
- Company Stock Availability
- +44 (0)1480 402 400 [option 1]
- Atc Code
- J01GB06
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Tillomed Laboratories Limited
220 Butterfield
Great Marlings
Luton, LU2 8DL
United Kingdom
- Authorisation Number
- PL 11311/0604
- Authorisation Date
- 18/03/2025
- Instruction Authorisation Holder
- Tillomed Laboratories Limited
220 Butterfield
Great Marlings
Luton, LU2 8DL
United Kingdom
- Instruction Authorisation Number
- PL 11311/0604
- Instruction Authorisation Date
- 18/03/2025
- Instruction Composition
- Each ml contains 250 mg of amikacin (as sulphate).
Each 2 ml vial contains 500 mg of amikacin (as sulphate).
Each 4 ml vial contains 1 g of amikacin (as sulphate).
Excipients with known effect:
Each 2 ml vial contains 6.6 mg of sodium metabisulphite (E223) (equivalent to 4.44 mg SO2) and 13.32 mg of sodium.
Each 4 ml vial contains 13.2 mg of sodium metabisulphite (E223) (equivalent to 8.9 mg SO2) and 26.65 mg of sodium.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Solution for injection/infusion.
Clear, colourless to light straw-coloured solution.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Amikacin is indicated in the treatment of following infections in adults and pediatric patients including neonates (see section 5.1)
- Hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP)
- Complicated Urogenital tract infections including pyelonephritis
- Complicated Intraabdominal infections
- Endocarditis (only in combination with other antibiotics),
- Infected burns
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Amikacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.4.2 Posology and method of administration
Posology
The dose must be adjusted individually, based on body weight and renal function, and the serum concentration must be monitored regularly.
Renal function status should be estimated by measuring the serum creatinine concentration or by calculating the endogenous creatinine clearance value. The BUN (blood urea nitrogen) test is much less reliable for this purpose. Evaluations of renal function should be done regularly during treatment.
Amikacin can be given intramuscularly or intravenously in the same dosage. For intravenous administration, the dose is added to the appropriate infusion solution (see section 6.6) and administered as an infusion over 30-60 minutes.
Amikacin must not be mixed with other medicines, but must be administered separately according to the recommended dose and method of administration.
\*Special recommendation for intravenous administration in children:\*
In paediatric patients, the amount of diluent is adjusted according to how much amikacin can be tolerated by the patient. The solution should usually be infused over 30 to 60 minutes. Infants should be given a 1 to 2 hour infusion.
\*Adults and children over 12 years of age:\*
The recommended intramuscular or intravenous dose for adults and adolescents with normal renal function (creatinine clearance ≥50 mg/min) is 15mg/kg/day given either as a single daily dose or as several equal doses (e.g. 7.5 mg/kg all 12 hours, or 5mg/kg every 8 hours).
The total daily dose should not exceed 1.5g. For endocarditis and febrile neutropenic patients, dosing should be twice a day, as there is insufficient data to support once-daily dosing.
\*Children from 4 weeks to 12 years of age:\*
The recommended intramuscular or intravenous (slow intravenous infusion) dosage for children with normal renal function is 15-20 mg/kg/day, given either as a single daily dose of 15-20mg/kg or divided into two doses of 7.5 mg/kg every 12 hours. For endocarditis and febrile neutropenic patients, dosing should be twice a day, as there is insufficient data to support once-daily dosing.
A once daily/extended interval dose regimen should be avoided in children over 1 month of age with a creatinine clearance less than 20 ml/minute/1.73 m2.
\*Neonates:\*
An initial bolus dose of 10mg/kg, then 7.5mg/kg every 12 hours (see sections 4.4 "Special warnings and precautions for use" and 5.2 "Pharmacokinetic properties").
\*Preterm infants:\*
The recommended dose for preterm infants is 7.5mg/kg every 12 hours (see sections 4.4 "Special warnings and precautions for use" and 5.2 "Pharmacokinetic properties").
The normal treatment duration is 7-10 days. The total daily dose for both routes of administration should not exceed 15-20 mg/kg/day. In severe and complicated infections, where treatment for more than 10 days is considered, the use of Amikacin should be re-evaluated, and if treatment is continued, renal, auditory and vestibular function should be monitored, as well as amikacin blood levels.
If clear clinical response does not occur within 3-5 days, treatment should be stopped and antibiotic susceptibility of the causative organism should be rechecked. Failure to response may be due to resistance of the organism or the presence of a septic foci, which requires surgical drainage.
The safety of treatment longer than 14 days has not been established.
\*Endocarditis:\*
In endocarditis caused by Enterococcus faecalis or alpha streptococcus, Amikacin should be combined with ampicillin and benzylpenicillin, respectively.
In case of endocarditis caused by staphylococci, Amikacin should be combined with an isoxazolyl penicillin.
\*Neutropenic patients:\*
When treating neutropenic patients, Amikacin should be combined with piperacillin and tazobactam.
In the case of serious infections of unknown etiology, Amikacin should be combined with a beta-lactam antibiotic while waiting for a culture and resistance report.
\*Systemic infections caused by Pseudomonas:\*
The adult dose may be increased to 500 mg every eight hours but should neither exceed 1.5 g/day nor be administered for a period longer than 10 days. A maximum total adult dose of 1.5 g should not be exceeded.
In case of systemic infection caused by \*Pseudomonas aeruginosa\*, Amikacin can be combined with a beta-lactam antibiotic effective against \*Pseudomonas aeruginosa\*.
When treating infections caused by both aerobic and anaerobic bacteria, Amikacin should be combined with a preparation active against anaerobic bacteria.
Urinary tract infections (other than pseudomonal infections):
7.5 mg/kg/day in two equally divided doses (equivalent to 250 mg twice daily in adults). As the activity of amikacin is enhanced by increasing the pH, a urinary alkalizing agent may be administered concurrently.
\*\*Impaired renal function\*\*
It is especially important in the case of impaired renal function that the serum concentration of amikacin is monitored regularly.
Since amikacin is mainly eliminated by the renal by glomerular filtration, the rate of elimination depends on the patient's renal function and the recommended daily dose should therefore be adapted to renal function. If renal function is impaired and the dose is not reduced and/or the dosing intervals are not extended, abnormally high and possibly toxic concentrations can be achieved in blood and tissues due to accumulation. The degree of renal impairment should be controlled by determining serum creatinine or creatinine clearance.
As the effect of aminoglycosides is correlated to Cmax (see section 5.1), all patients are initially given a normal dose (15 mg/kg body weight). In patients with mild to moderate renal impairment, the dosing interval is based on the trough value, see “Treatment control”. There are no data for recommendations for repeated dosing in patients with severe renal impairment, i.e. where an adequate trough value is not reached within 48 hours.
\*Haemodialysis:\*
The documentation for dosing in patients undergoing haemodialysis is deficient. Commonly used dosage is 5 mg/kg body weight given after each dialysis session.
\*Peritoneal dialysis:\*
Patients who undergo peritoneal dialysis twice a week are given 5 mg/kg body weight after each dialysis session. Patients who undergo peritoneal dialysis every other day are given 5 mg/kg after the first dialysis session and 2.5 mg/kg after the following dialysis sessions.
\*Once daily/extended interval dosing\*
Patients with renal impairment in whom once daily dosing would be considered appropriate if their renal function were normal may receive extended interval dosing. The initial dose may be the same as in normal renal function. The dose interval should be at least 24 hours and extended according to the degree of renal impairment and the results of serum amikacin level measurements. In severe renal impairment, the initial dose may have to be reduced. Once daily or extended interval dosing should be avoided in patients with a creatinine clearance less than 20 ml/minute.
\*Reduced dose at fixed intervals:\*
If patients with renal impairment are given amikacin at fixed time intervals, the dose must be reduced. In these patients, the serum amikacin concentration should be measured to ensure accurate administration and to avoid excessive serum concentrations. If a determination of serum concentration is not possible and the patient's condition is stable, serum creatinine and creatinine clearance rates are the most readily available indicators of the extent of renal dysfunction and the consequent reduction in dose.
\*Multiple daily dosing\*
In patients with renal impairment in whom multiple daily dosing at fixed intervals would be considered appropriate if their renal function were normal, the dose must be reduced while the dose interval is maintained. Serum amikacin concentrations should be measured and creatinine clearance should be estimated regularly. Treatment should be initiated by administering a normal dose, 7.5 mg/kg, as a loading dose. This dose is the same as the normally recommended dose which would be calculated for a patient with a normal renal function. To initially determine the size of maintenance doses administered after 12 hours, the loading dose should be reduced in proportion to the reduction in the patient's creatinine clearance rate:
Maintenance dose every 12 hours =
(CrCl = creatinine clearance rate)
Intraperitoneal use
Following exploration for established peritonitis, or after peritoneal contamination due to faecal spill during surgery, Amikacin may be used as an irrigant after recovery from anaesthesia in concentrations of 0.25% (2.5 mg/mL). If instillation is desired in adults, a single dose of 500 mg is diluted in 20 ml of sterile distilled water and may be instilled through a polyethylene catheter sutured into the wound at closure. If possible, instillation should be postponed until the patient has fully recovered from the effects of anaesthesia and muscle-relaxing drugs.
Monitoring
The renal function status should be evaluated by measuring the serum creatinine concentration or preferably by estimation of creatinine clearance. Blood urea nitrogen (BUN) is far less reliable for this purpose. Assessment of renal function should be performed at the start of therapy and should be re-evaluated at regular intervals during treatment.
Amikacin concentrations in serum should be measured in all patients receiving parenteral amikacin and must be measured in obesity, if high doses are being given, the elderly and in cystic fibrosis. Both peak and trough serum concentrations should be measured intermittently during therapy to ensure adequate but not excessive serum levels. In patients receiving multiple daily dosing peak concentrations (30-90 minutes after injection) of above 35μg/ml and trough concentrations (just before the next dose) of above 10μg/ml should be avoided.
In patients receiving once daily (or extended interval) dosing pre-dose ('trough') concentration should be less than 5 mcg/ml. Peak concentrations (approximately 60 minutes after administration) may exceed 35 mcg/ml.
If the pre-dose ('trough') concentration is high, the interval between doses must be increased. If the post-dose ('peak') concentration is high, the dose must be decreased.
Auditory and vestibular function should also be monitored during treatment, in particular if longer treatment duration (>7-10 days) is considered.
\*Treatment Control\*
Serum amikacin concentrations should be monitored to ensure therapeutic, but not excessively high, levels. It is recommended that serum samples be taken on the second day of treatment and then regularly, 2-3 times a week, during treatment. Trough values (just before the next dosing session) should not exceed 10 micrograms/ml. A progressive increase in the trough value reveals an ongoing accumulation, in which case the dosing interval should be extended.
Amikacin, like other aminoglycosides, is potentially nephrotoxic and ototoxic. Renal function, hearing and balance should, if possible, be checked regularly during amikacin treatment. It is extremely important to follow the dosage recommendations and to keep the patient well hydrated.
Method of administration
\*Intramuscular use or intravenous use after dilution\*.
The solution for intravenous use is prepared by adding the desired dose to 100ml or 200ml of sterile diluent such as normal saline or 5% dextrose in water or any other compatible solution. The solution is administered to adults over a 30 to 60-minute period.
In paediatric patients the amount of diluents used will depend on the amount of amikacin tolerated by the patient. The solution should normally be infused over a 30 to 60-minute period. Infants should receive a 1 to 2-hour infusion.
Amikacin should not be physically premixed with other drugs, but should be administered separately according to the recommended dose and route.
For the dilution of Amikacin see section 6.6.
Other routes of administration
Amikacin in concentrations of 0.25% (2.5 mg/ml) may be used satisfactorily as an irrigating solution in abscess cavities, the pleural space, the peritoneum and the cerebral ventricles.4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Due to the known cross sensitivities, previous hypersensitivity reactions or serious toxic reactions with any aminoglycosides may be a contraindication for the use of other aminoglycosides.
• Because of its sulphite content, Amikacin must not be used in asthmatics with sulphite hypersensitivity.4.4 Special warnings and precautions for use
\*\*Allergic reactions\*\*
Amikacin contains sodium metabisulfite which may cause severe hypersensitivity reactions in susceptible individuals, including anaphylactic symptoms and life-threatening bronchial spasms (bronchospasm). Sulfite sensitivity is generally uncommon and more frequent in asthmatics than in non-asthmatics.
Caution should be applied to patients with existing renal insufficiency, or with existing auditory or vestibular damage. Patients treated with parenteral aminoglycosides should be under close clinical observation due to potential ototoxicity and nephrotoxicity associated with treatment. The safety of treatment for longer than 14 days has not been established.
\*\*Neuro/Ototoxicity\*\*
Neurotoxicity manifesting as vestibular and/or bilateral auditory ototoxicity may occur in patients treated with aminoglycosides. The risk of aminoglycoside-induced ototoxicity is greater in patients with impaired renal function or in those where the duration of treatment is extended beyond 5-7 days, even in healthy patients. Often, deafness at high frequencies appears first and can only be detected by audiometric testing. Dizziness may occur and may be evidence of vestibular damage. Other signs of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. Patients who develop cochlear or vestibular damage do not need to have symptoms during treatment that alert them of eighth cranial nerve damage. Total or partially irreversible bilateral deafness or disabling vertigo may occur after discontinuation of the drug.
Aminoglycoside Induced ototoxicity is usually irreversible.
There is an increased risk of ototoxicity in patients with mitochondrial DNA mutations (particularly the nucleotide 1555 A to G substitution in the 12S rRNA gene), even if aminoglycoside serum levels are within the recommended range during treatment. Alternative treatment options should be considered in such patients.
In patients with a family history of relevant mutations or aminoglycoside induced deafness, alternative treatments or genetic testing prior to administration, should be considered.
\*\*Neuromuscular toxicity\*\*
Neuromuscular blockade and respiratory paralysis have been reported following parenteral injection, topical installation (as in orthopaedic flushing and abdominal lavage, or with local empyema treatment) and after oral administration of aminoglycosides. The risk of respiratory paralysis when administering aminoglycosides irrespective of the route of administration should be considered, especially in patients receiving anesthetics or neuromuscular blockers (see section 4.5 Interactions with other medications and other forms of interaction "). If neuromuscular blockade occurs, calcium salts may relieve respiratory paralysis but mechanical ventilation may be necessary.
In animal studies, neuromuscular blockade and muscular paralysis have been reported after administration of high doses of amikacin.
Aminoglycosides should be used with caution in patients with muscular disorders such as myasthenia gravis or parkinsonism as these drugs may aggravate muscle weakness due to their potential curare-like effect on the neuromuscular junction.
\*Renal toxicity:\*
Aminoglycosides are potentially nephrotoxic. Renal toxicity appears independent of plasma obtained at the peak (Cmax). The risk of nephrotoxicity is increased in patients with impaired renal function and in patients receiving high doses or prolonged treatment.
Patients should be well hydrated during treatment and renal function should be assessed by the usual methods prior to starting therapy and daily during the course of treatment. A reduction of dosage is required if evidence of renal dysfunction occurs, such as presence of urinary casts, white or red cells, albuminuria, decreased creatinine clearance, decreased urine specific gravity, increased BUN, serum creatinine, or oliguria. If azotemia increases, or if a progressive decrease in urinary output occurs, treatment should be stopped.
Elderly patients may have reduced renal function which may not be seen in the routine screening tests such as BUN (blood urea nitrogen) or serum creatinine. A creatinine clearance determination may be more helpful. Monitoring of renal function in elderly patients during treatment with aminoglycosides is particularly important.
Renal function and function of the eighth cranial nerve should be closely monitored, especially in patients with known or suspected renal impairment at the onset of treatment and also in those whose renal function is initially normal but who develop signs of renal impairment during treatment.
Serum concentrations of amikacin should be monitored (when possible) to ensure adequate levels and to avoid potential toxic levels. The urine should be examined for decreased density, increased excretion of proteins and the presence of cells or casts. BUN (blood urea nitrogen), serum creatinine, or creatinine clearance should be measured periodically. Repeat audiograms should be performed (if possible), especially in high-risk patients. Evidence of ototoxicity (dizziness, tinnitus, ringing in the ears and hearing loss) or nephrotoxicity require discontinuation of the drug or dose adjustment.
Concomitant and/or sequential systemic, oral, or topical use of other neurotoxic or nephrotoxic products, particularly bacitracin, cisplatin, amphotericin B, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides, should be avoided. Other factors that may increase risk of toxicity are advanced age and dehydration.
Inactivation of aminoglycosides is clinically significant only in patients with severe renal impairment. Inactivation may persist in body fluid samples collected for analysis, resulting in incorrect aminoglycoside readings. Such samples should be handled properly (analyzed immediately, frozen, or treated with beta-lactamase).
Diarrhoea/pseudomembranous colitis caused by \*Clostridium difficile\* occurs. Patients with diarrhoea must therefore be monitored closely.
\*\*Other\*\*
Aminoglycosides are quickly and almost totally absorbed when they are applied topically, except to the urinary bladder, in association with surgical procedures. Irreversible deafness, renal failure and death due to neuromuscular blockade have been reported following irrigation of both small and large surgical fields with an aminoglycoside preparation.
Prolonged antibiotic use may occasionally lead to overgrowth of resistant pathogens. The patient should be constantly monitored in this regard. Should a superinfection occur during therapy, appropriate measures must be taken.
Macular infarction sometimes leading to permanent loss of vision has been reported following intravitreous administration (injection into the eye) of amikacin.
\*\*Paediatric use\*\*
Aminoglycosides should be used with caution in premature and neonatal infants because of the renal immaturity of these patients and the resulting prolongation of serum half-life of these drugs.
\*\*Amikacin contains sodium\*\*
2 ml vial
This medicine contains less than 1 mmol sodium (23mg) per 2ml vial, that is to say essentially 'sodium-free'.
4 ml vial
This medicinal product contains 26.65 mg sodium per 4ml vial, equivalent to 1.33% of the WHO recommended maximum daily intake of 2g sodium for an adult.4.5 Interaction with other medicinal products and other forms of interaction
Concomitant or repeated use of other neurotoxic, ototoxic or nephrotoxic agents, particularly bacitracin, cisplatin, amphotericin B, cyclosporine, tacrolimus, cephaloridine, paromomycin, viomycin, polymyxin B, colistimethate/colistin, vancomycin, or other aminoglycosides should be avoided regardless of systemic or local administration due to the risk of additive effects. Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins. Concomitant treatment with a cephalosporin may result in falsely elevated creatinine serum level determinations.
The risk of ototoxicity is increased when amikacin is used in conjunction with rapidly acting diuretic drugs, particularly when the diuretic is administered intravenously. Diuretics may enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. Such agents include furosemide and ethacrynic acid which is itself an ototoxic agent. Irreversible deafness may result.
A reduction in serum activity of aminoglycosides may occur with concomitant use of penicillin-type drugs.
There is an increased risk of hypocalcaemia when aminoglycosides are administered with bisphosphonates.
There is an increased risk of nephrotoxicity and possibly of ototoxicity when aminoglycosides are administered with platinum compounds.
Concomitantly administered thiamine (vitamin B1) may be destroyed by the reactive sodium metabisulfite component of the amikacin sulfate formulation.
Indomethacin may increase the plasma concentration of amikacin in neonates.
In patients receiving anaesthetics or muscle-relaxing agents (such as d-tubocurarine, succinylcholine, decamethonium, atracurium, rocuronium, vecuronium) or in patients receiving massive transfusions of citrate-anticoagulated blood) as neuromuscular blockade and consequent respiratory depression may occur.
Some antibiotics could, in rare cases, reduce the effectiveness of oral contraceptives by interfering with the bacterial hydrolysis of steroid conjugates in the gut and thus the reabsorption of unconjugated steroid. Thereby, the plasma levels of active steroid would decrease. This unusual interaction would occur in women with high biliary excretion of steroid conjugates. This interaction has not been reported for amikacin.4.6 Fertility, pregnancy and lactation
Pregnancy
Amikacin should be used in pregnant women and newborns only if clearly indicated and under medical supervision (see section 4.4).
There is limited data on the use of aminoglycosides in pregnancy.
Aminoglycosides can affect the development of the embryo / foetus in the womb. Aminoglycosides cross the placental barrier and there have been reports of total, irreversible, bilateral congenital deafness in children whose mothers were treated with streptomycin during pregnancy.
Although adverse reactions to the foetus or neonate in pregnant women who have been treated with other aminoglycosides have not been reported, there is potential for harm.
If amikacin is used during pregnancy or if the patient becomes pregnant during treatment with this drug, the patient should be informed of the possible risks to the foetus.
Breast-feeding
It is not known if amikacin passes into the breast milk. The decision should be made to either stop breastfeeding or stop the treatment.
Fertility
In reproduction toxicity studies in mice and rats, no effects on fertility or foetal toxicity were reported.4.7 Effects on ability to drive and use machines
No studies on the ability to drive and the use of machines have been performed. However, the occurrence of some side effects (see section 4.8) may impair the ability to drive vehicles and operate machinery.4.8 Undesirable effects
All aminoglycosides can induce ototoxicity, renal toxicity and neuromuscular blockade. The risk of these toxicities is greater in patients with impaired renal function, in patients receiving more than the recommended dose, prolonged treatment and in patients treated with other ototoxic or nephrotoxic drugs (see section 4.4 "Special warnings and precautions for use").
The frequency of the side effects listed below is defined using the following conventions:
very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (frequency cannot be estimated from the available data).
The frequency of the adverse reactions listed below is defined by the following groupings:
| | | |
| --- | --- | --- |
| \*\*MedDRA system organ class\*\* | \*\*Frequency\*\* | \*\*Adverse event\*\* |
| Infections and Infestations | Uncommon | Super infection or colonization with resistant bacteria or yeasts a. |
| Blood and lymphatic system disorders | Rare | Anaemia, eosinophilia, granulocytopenia, leukopenia, thrombocytopenia |
| Immune system disorders | Not known | Anaphylactic response (anaphylactic reaction, anaphylactic shock and anaphylactoid reaction), hypersensitivity |
| Metabolism and nutrition disorders | Rare | Hypomagnesemia |
| Nervous system disorders | Common | Dizziness |
| Rare | Tremor a, paraesthesiaa, headache, balance disorders |
| Not known | Acute muscular paralysisa |
| Eye disorders | Rare | Blindnessb, retinal infarctionb |
| Ear and labyrinth disorders | Common | Vestibular disorders with nausea |
| Rare | Tinnitusa, hearing lossa |
| Not known | Deafness a, neurosensory deafness a |
| Cardiovascular | Rare | Hypotension, hypotonia, thrombophlebitis tachycardia, myocarditis |
| Respiratory, thoracic and mediastinal disorders | Not known | Apnoea, bronchospasm |
| Gastrointestinal disorders | Uncommon | Vomiting, nausea |
| Hepatobiliary disorders | Uncommon | Elevation of liver enzymes in plasma (SGOT, SGPT, LDH, alkaline phosphatase and bilirubin) |
| Skin and subcutaneous tissue disorders | Uncommon | Rash |
| Rare | Pruritus, urticaria |
| Musculoskeletal and connective tissue disorders | Rare | Arthralgia, muscle contractionsa |
| Renal and urinary disorders | Common | Proteinuria, urea increase |
| Rare | Oliguriaa, serum creatinine increasea, albuminuriaa, azotemiaa, presence of red and white blood cells in the urinea |
| Not known | acute renal failure, toxic nephropathy, cells in the urinea |
| General disorders and administration site conditions | Rare | Fever |
| Not known | Pain in the injection site |
a. See section 4.4 "Special warnings and precautions for use"
b. Amikacin is not formulated for intravitreal use. Blindness and retinal infarction have been reported following intravitreal administration (injection into the eye) of amikacin.
Description of selected adverse reactions
Cases of skin and mucosal reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported, however with an unclear connection.
\*Kidney and urinary tract disorders\*
Nephrotoxicity is manifested as increased excretion of tubule epithelia, cylindruria, increase in β2-microglobulin excretion, enzyme excretion via urine (e.g. alanine aminopeptidase, glutamine transferase, β-galactosidase, N-acetyl-glucosaminidase), azotemia, decrease in urine osmolarity, increase in blood urea nitrogen and serum creatinine, decrease in creatinine clearance. In case of minor irritations (albumin, erythrocytes, leukocytes or cylinders in urine) the fluid intake should be increased. After discontinuation of the drug, renal impairment is usually reversible.
As with all aminoglycosides, there have been reports of nephrotoxicity and acute renal failure following approval of amikacin.
\*Disorders of the ear and the labyrinth\*
Ototoxic reactions involving the 8th cranial nerve occur in approximately 0.5 - 5% of the treated patients. This may involve vestibular or cochlear function (see section 4.4 "Special warnings and precautions for use").
When treating with amikacin, special attention should be paid to cochlear damage. These are manifested as tinnitus, pressure in the ears and initially merely as audiometrically detectable decrease of acoustic perceptions in the high frequency range (> 4000 Hertz) above the speech range. However, hearing loss can develop to complete, irreversible deafness despite discontinuation of the aminoglycoside. Vestibular disorders manifest in initial symptoms such as dizziness, nausea, and vomiting. In the clinical examination usually a nystagmus is detected. At the first sign of hearing or balance disorders, amikacin therapy should be discontinued.
\*Disorder of the nervous system\*
\*Neuromuscular blockades:\*
Specific risks are very rare when taking aminoglycosides. The occurrence of neuromuscular blockade, which can lead to respiratory arrest, can occur especially with intrapleural or intraperitoneal administration. The neuromuscular blocking properties of the aminoglycosides are enhanced by inhalation narcotics or muscle relaxants or curare-like drugs. Particularly at risk are patients with myasthenia gravis. Respiratory paresis requires artificial respiration. In addition, the application of potassium salts may be considered as a countermeasure.
\*Immune system disorders\*
Due to the content of sulfite it can lead to hypersensitivity reactions that may manifest as vomiting, diarrhea, wheezing, acute asthma attack, disturbance of consciousness or shock in individual cases, especially in bronchial asthma. These reactions can vary widely individually and can lead to life-threatening conditions
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
In case of overdose, there is a significant risk of nephro, oto- and neurotoxic (neuromuscular blockade) reactions. Respiratory neuromuscular blockade should be immediately treated, including the administration of calcium in ionised form (for example as gluconate or lactobionate in 10-20% solution) (see section 4.4 "Special warnings and precautions for use"). In cases of overdose or toxic reactions, amikacin can be removed from the blood by peritoneal or haemodialysis. Continuous arteriovenous haemofiltration also leads to a reduction of amikacin. In neonates, an exchange transfusion may be considered.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antibiotics for systemic use, aminoglycoside antibiotics, ATC code: J01GB06.
Amikacin is a kanamycin-derived semisynthetic aminoglycoside antibiotic which works by stopping the bacteria's protein synthesis. The substance has a bactericidal effect.
Mechanism of action
The mechanism of action of amikacin is due to a disruption of protein biosynthesis on the bacterial ribosome by interaction with the rRNA and subsequent inhibition of translation. This results in a bactericidal effect.
\*Relationship between pharmacokinetics and pharmacodynamics\*
The efficacy depends essentially on the quotient of maximum serum concentration (Cmax) and minimal inhibitory concentration (MIC) of the pathogen.
\*Resistance mechanisms\*
Resistance to amikacin may be due to the following mechanisms:
• Enzymatic Inactivation: Enzymatic modification of aminoglycoside molecules is the most common mechanism of resistance. Acetyltransferases, phosphotransferases or nucleotidyltransferases are responsible for this, most of which are plasmid-encoded. Amikacin is highly stable to aminoglycoside-inactivating enzymes. It can therefore inhibit bacteria that are resistant to gentamicin and other aminoglycosides.
• Reduced penetration and active efflux: These resistance mechanisms are mainly found in \*Pseudomonas aeruginosa\*.
• Alteration of the target structure: Modifications within the ribosomes are the cause of resistance.
There is partial cross-resistance of amikacin with other aminoglycoside antibiotics.
\*Threshold values\*
The assay of amikacin is carried out using usual serial dilution. The following minimum inhibitory concentrations for sensitive and resistant pathogens have been established:
EUCAST Clinical MIC Breakpoints for amikacin (EUCAST Clinical Breakpoint table version 13.0, valid from 01-01-2023).
| | |
| --- | --- |
| \*\*Pathogen\*\* | \*\*Species-related breakpoints, mg / L of amikacin\*\* \*\*(S ≤ / R >)\*\* |
| \*Enterobacterales\* (systemic infections) | 8/81 |
| \*Enterobacterales\* (infections originating from the urinary tract) | 8/8 |
| \*Pseudomonas\* spp. (systemic infections) | 16/161 |
| \*Pseudomonas\* spp. (infections originating from the urinary tract) | 16/16 |
| \*Acinetobacter\* spp. (systemic infections) | 8/81 |
| \*Acinetobacter\* spp. (infections originating from the urinary tract) | 8/8 |
| \*Staphylococcus\* spp. (\*S.aureus\*) | 16/161 |
| \*Staphylococcus\* spp. (coagulase-negative staphylococci | 16/16 |
| \*Enterococcus spp.\* | Note2/ Note2 |
| \*Viridans group streptococci\* | Note2/ Note2 |
| \*Haemophilus influenzae\* | IE/IE |
| \*Moraxella catarrhalis\* | IE/IE |
| PK-PD (Non-species related) breakpoints | 1/1 |
1 For systemic infections, aminoglycosides should be used in combination with other active therapy. In this circumstance, the value in brackets can be used to distinguish between wild type organisms and organisms with acquired resistance mechanisms.
Note2 - Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
IE- Insufficient evidence
The prevalence of acquired resistance of individual species may vary over place and over time. Therefore, local information about the resistance situation is required, especially for the adequate treatment of severe infections. If the efficacy of amikacin is questionable due to the local resistance situation, expert therapy counselling should be sought. Particularly in the case of severe infections or treatment failures, a microbiological diagnosis with detection of the pathogen and its sensitivity to amikacin should be sought.
| |
| --- |
| \*\*Sensitive Species\*\* \*\*Aerobic gram-positive micro-organisms\*\* Staphylococcus aureus Staphylococcus haemolyticus Staphylococcus hominis \*\*Aerobic gram-negative micro-organisms\*\* Coagulase negative staphylococci Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzae Klebsiella oxytoca Klebsiella pneumoniae Morganella morganii Proteus mirabilis Proteus vulgaris Providencia Pseudomonas aeruginosa 1) Salmonella enterica (enteritis salmonella) Serratia liquefaciens ° Serratia marcescens Shigella spp. \*\*Species in which acquired resistance can be a problem\*\* \*\*Aerobic gram-positive micro-organisms\*\* Staphylococcus epidermis \*\*Aerobic gram-negative micro-organisms\*\* Acinetobacter baumannii \*\*Naturally resistant species\*\* \*\*Aerobic gram-positive micro-organisms\*\* Enterococcus spp. Streptococcus spp. Pneumococcus \*\*Aerobic gram-negative micro-organisms\*\* Burkholderia cepacia Stenotrophomonas maltophilia Meningococcus \*\*Anaerobic micro-organisms\*\* Bacteroides spp. Prevotella spp. Clostridium difficile Legionella \*\*Other micro-organisms\*\* Chlamydia spp. Chlamydophila spp. Mycoplasma spp. Urea plasma urealyticum |
oThere were no latest data when the tables were published. The primary literature, standard works and therapy recommendations presume sensitivity.
1) For isolates of particular patient groups, e.g. Patients with cystic fibrosis, the resistance rate ≥10%.
Resistance occurs (1-10%) in Pseudomonas aeruginosa and is common (>10%) in coagulase-negative staphylococci.
In combination with a beta-lactam antibiotic, a synergistic effect is often achieved against most bacteria including streptococci and enterococci.5.2 Pharmacokinetic properties
Amikacin is rapidly absorbed after intramuscular administration. Doses of 250 mg and 500 mg intramuscularly give maximum serum concentrations of approximately 12 micrograms/ml and approximately 21 micrograms/ml after one hour, respectively. After 10 hours, the serum concentration is approximately 0.3 micrograms/ml and approximately 2.1 micrograms/ml, respectively.
In intravenous infusion of 500 mg (7.5 mg/kg) over 30 minutes, a maximum serum concentration of an average of 38 micrograms/ml is obtained immediately after the infusion and 30 minutes after the end of the infusion a concentration of 24 micrograms/ml. In the case of infusion of 15 mg/kg, the corresponding concentrations are 77 micrograms/ml and 47 micrograms/ml, respectively.
Plasma protein binding of amikacin is low and ranges from 0-11%. The volume of distribution is about 24 liters in an adult or about 28% of body weight. Amikacin rapidly distributes itself to different tissues after parenteral administration. Amikacin passes into the cerebrospinal fluid in small amounts in intact meninges, while the blood- CSF barrier is penetrated more easily in meningitis. There is no accumulation with repeated dosing.
Amikacin is not metabolized and is excreted in active form almost exclusively by glomerular filtration. In normal renal function, the half-life is about 2 hours and 92% of a given dose is excreted unchanged in the urine within 8 hours and 98% within 24 hours.
In case of impaired renal function, excretion is significantly delayed.
Data from trials with multiple daily doses show that levels in cerebrospinal fluid in normal children are about 10-20% of the serum concentration and may reach up to 50% in meningitis.
\*Intramuscular and intravenous administration:\*
Renal elimination of amikacin is reduced in newborns and especially in premature infants.
\*Experiences in children\*
Data from dosing studies on a daily basis show that levels in CSF in normal children are around 10 to 20% of serum concentrations and may reach 50% in meningitis.
The elimination of amikacin was reduced in newborns and especially in preterm infants.
In a study of newborns (aged 1-6 days old) children were grouped by birth weight (<2000 g, 2000-3000 g and > 3000 g). Amikacin was given intramuscularly and/or intravenously at a dose of 7.5mg/kg. The neonatal clearance > 3000g was 0.84 ml/min/kg and the terminal half-life was about 7 hours. In this group, the initial volume of distribution was 0.3 ml/kg and the volume of distribution at steady state was 0.5 ml/kg. In the lower birth weight groups, the clearance/kg was lower and the half-life longer. Repeated dosing every 12 hours in all the specified groups showed no accumulation after 5 days.5.3 Preclinical safety data
No long-term studies have been performed to evaluate the carcinogenic or mutagenic potential. Studies in rats have shown that daily doses up to 10 times recommended dose for humans did not cause any adverse effects on male and female fertility.
Neuromuscular blockade has been seen in laboratory animals after high doses (see section 4.4).
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Sodium metabisulfite (E223)
Sodium citrate dihydrate
Sulfuric acid
Water for injection6.2 Incompatibilities
Aminoglycosides such as amikacin should not be combined with other medicines, but must be administered separately. Aminoglycosides and penicillins can inactivate each other \*in vitro\*, with loss of antibacterial activity.6.3 Shelf life
2 years
Intended for single use. Residual quantities are to be discarded.
After dilution:
Chemical and physical in use stability has been demonstrated for 36 hours at 25°C, 30 days at -15°C and 60 days at 4°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.6.5 Nature and contents of container
Amikacin 500mg/2ml (250mg/ml) is available as a clear, colourless to light straw-coloured solution, packed in a 2ml clear Type-I glass vial with a dark grey, chlorobutyl rubber stopper and a flip off seal.
2 ml (500 mg): 1 and 5 vials
Amikacin 1g/4ml (250mg/ml) is available as a clear, colourless to light straw-coloured, solution, packed in a 5ml clear Type-I glass vial with a dark grey, chlorobutyl rubber stopper and a flip off seal.
4 ml (1,000 mg): 1 and 5 vials
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
No special requirements for disposal.
Like all parenterals, Amikacin should be checked for particulate matter and discoloration before use. Only clear solutions which, at most, are slightly yellow in colour should be used. A pale yellow solution is not an indicator of reduced efficacy.
For intravenous infusion, Amikacin is given at the calculated dose in 100ml or 200ml of sterile infusion solution. The solution is administered to adults in a 30-60 minute infusion. For dosing in adults and children see section 4.2 "Posology and method of administration".
Suitable solvents for intravenous infusion are:
0.9% NaCl solution for infusion
5% glucose solution for infusion
Ringer's lactate solution without 5% glucose
- Instruction Content
- ## Composition
Each ml contains 250 mg of amikacin (as sulphate).
Each 2 ml vial contains 500 mg of amikacin (as sulphate).
Each 4 ml vial contains 1 g of amikacin (as sulphate).
Excipients with known effect:
Each 2 ml vial contains 6.6 mg of sodium metabisulphite (E223) (equivalent to 4.44 mg SO2) and 13.32 mg of sodium.
Each 4 ml vial contains 13.2 mg of sodium metabisulphite (E223) (equivalent to 8.9 mg SO2) and 26.65 mg of sodium.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Solution for injection/infusion.
Clear, colourless to light straw-coloured solution.
## Clinical Particulars
4.1 Therapeutic indications
Amikacin is indicated in the treatment of following infections in adults and pediatric patients including neonates (see section 5.1)
- Hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP)
- Complicated Urogenital tract infections including pyelonephritis
- Complicated Intraabdominal infections
- Endocarditis (only in combination with other antibiotics),
- Infected burns
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Amikacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.4.2 Posology and method of administration
Posology
The dose must be adjusted individually, based on body weight and renal function, and the serum concentration must be monitored regularly.
Renal function status should be estimated by measuring the serum creatinine concentration or by calculating the endogenous creatinine clearance value. The BUN (blood urea nitrogen) test is much less reliable for this purpose. Evaluations of renal function should be done regularly during treatment.
Amikacin can be given intramuscularly or intravenously in the same dosage. For intravenous administration, the dose is added to the appropriate infusion solution (see section 6.6) and administered as an infusion over 30-60 minutes.
Amikacin must not be mixed with other medicines, but must be administered separately according to the recommended dose and method of administration.
\*Special recommendation for intravenous administration in children:\*
In paediatric patients, the amount of diluent is adjusted according to how much amikacin can be tolerated by the patient. The solution should usually be infused over 30 to 60 minutes. Infants should be given a 1 to 2 hour infusion.
\*Adults and children over 12 years of age:\*
The recommended intramuscular or intravenous dose for adults and adolescents with normal renal function (creatinine clearance ≥50 mg/min) is 15mg/kg/day given either as a single daily dose or as several equal doses (e.g. 7.5 mg/kg all 12 hours, or 5mg/kg every 8 hours).
The total daily dose should not exceed 1.5g. For endocarditis and febrile neutropenic patients, dosing should be twice a day, as there is insufficient data to support once-daily dosing.
\*Children from 4 weeks to 12 years of age:\*
The recommended intramuscular or intravenous (slow intravenous infusion) dosage for children with normal renal function is 15-20 mg/kg/day, given either as a single daily dose of 15-20mg/kg or divided into two doses of 7.5 mg/kg every 12 hours. For endocarditis and febrile neutropenic patients, dosing should be twice a day, as there is insufficient data to support once-daily dosing.
A once daily/extended interval dose regimen should be avoided in children over 1 month of age with a creatinine clearance less than 20 ml/minute/1.73 m2.
\*Neonates:\*
An initial bolus dose of 10mg/kg, then 7.5mg/kg every 12 hours (see sections 4.4 "Special warnings and precautions for use" and 5.2 "Pharmacokinetic properties").
\*Preterm infants:\*
The recommended dose for preterm infants is 7.5mg/kg every 12 hours (see sections 4.4 "Special warnings and precautions for use" and 5.2 "Pharmacokinetic properties").
The normal treatment duration is 7-10 days. The total daily dose for both routes of administration should not exceed 15-20 mg/kg/day. In severe and complicated infections, where treatment for more than 10 days is considered, the use of Amikacin should be re-evaluated, and if treatment is continued, renal, auditory and vestibular function should be monitored, as well as amikacin blood levels.
If clear clinical response does not occur within 3-5 days, treatment should be stopped and antibiotic susceptibility of the causative organism should be rechecked. Failure to response may be due to resistance of the organism or the presence of a septic foci, which requires surgical drainage.
The safety of treatment longer than 14 days has not been established.
\*Endocarditis:\*
In endocarditis caused by Enterococcus faecalis or alpha streptococcus, Amikacin should be combined with ampicillin and benzylpenicillin, respectively.
In case of endocarditis caused by staphylococci, Amikacin should be combined with an isoxazolyl penicillin.
\*Neutropenic patients:\*
When treating neutropenic patients, Amikacin should be combined with piperacillin and tazobactam.
In the case of serious infections of unknown etiology, Amikacin should be combined with a beta-lactam antibiotic while waiting for a culture and resistance report.
\*Systemic infections caused by Pseudomonas:\*
The adult dose may be increased to 500 mg every eight hours but should neither exceed 1.5 g/day nor be administered for a period longer than 10 days. A maximum total adult dose of 1.5 g should not be exceeded.
In case of systemic infection caused by \*Pseudomonas aeruginosa\*, Amikacin can be combined with a beta-lactam antibiotic effective against \*Pseudomonas aeruginosa\*.
When treating infections caused by both aerobic and anaerobic bacteria, Amikacin should be combined with a preparation active against anaerobic bacteria.
Urinary tract infections (other than pseudomonal infections):
7.5 mg/kg/day in two equally divided doses (equivalent to 250 mg twice daily in adults). As the activity of amikacin is enhanced by increasing the pH, a urinary alkalizing agent may be administered concurrently.
\*\*Impaired renal function\*\*
It is especially important in the case of impaired renal function that the serum concentration of amikacin is monitored regularly.
Since amikacin is mainly eliminated by the renal by glomerular filtration, the rate of elimination depends on the patient's renal function and the recommended daily dose should therefore be adapted to renal function. If renal function is impaired and the dose is not reduced and/or the dosing intervals are not extended, abnormally high and possibly toxic concentrations can be achieved in blood and tissues due to accumulation. The degree of renal impairment should be controlled by determining serum creatinine or creatinine clearance.
As the effect of aminoglycosides is correlated to Cmax (see section 5.1), all patients are initially given a normal dose (15 mg/kg body weight). In patients with mild to moderate renal impairment, the dosing interval is based on the trough value, see “Treatment control”. There are no data for recommendations for repeated dosing in patients with severe renal impairment, i.e. where an adequate trough value is not reached within 48 hours.
\*Haemodialysis:\*
The documentation for dosing in patients undergoing haemodialysis is deficient. Commonly used dosage is 5 mg/kg body weight given after each dialysis session.
\*Peritoneal dialysis:\*
Patients who undergo peritoneal dialysis twice a week are given 5 mg/kg body weight after each dialysis session. Patients who undergo peritoneal dialysis every other day are given 5 mg/kg after the first dialysis session and 2.5 mg/kg after the following dialysis sessions.
\*Once daily/extended interval dosing\*
Patients with renal impairment in whom once daily dosing would be considered appropriate if their renal function were normal may receive extended interval dosing. The initial dose may be the same as in normal renal function. The dose interval should be at least 24 hours and extended according to the degree of renal impairment and the results of serum amikacin level measurements. In severe renal impairment, the initial dose may have to be reduced. Once daily or extended interval dosing should be avoided in patients with a creatinine clearance less than 20 ml/minute.
\*Reduced dose at fixed intervals:\*
If patients with renal impairment are given amikacin at fixed time intervals, the dose must be reduced. In these patients, the serum amikacin concentration should be measured to ensure accurate administration and to avoid excessive serum concentrations. If a determination of serum concentration is not possible and the patient's condition is stable, serum creatinine and creatinine clearance rates are the most readily available indicators of the extent of renal dysfunction and the consequent reduction in dose.
\*Multiple daily dosing\*
In patients with renal impairment in whom multiple daily dosing at fixed intervals would be considered appropriate if their renal function were normal, the dose must be reduced while the dose interval is maintained. Serum amikacin concentrations should be measured and creatinine clearance should be estimated regularly. Treatment should be initiated by administering a normal dose, 7.5 mg/kg, as a loading dose. This dose is the same as the normally recommended dose which would be calculated for a patient with a normal renal function. To initially determine the size of maintenance doses administered after 12 hours, the loading dose should be reduced in proportion to the reduction in the patient's creatinine clearance rate:
Maintenance dose every 12 hours =
(CrCl = creatinine clearance rate)
Intraperitoneal use
Following exploration for established peritonitis, or after peritoneal contamination due to faecal spill during surgery, Amikacin may be used as an irrigant after recovery from anaesthesia in concentrations of 0.25% (2.5 mg/mL). If instillation is desired in adults, a single dose of 500 mg is diluted in 20 ml of sterile distilled water and may be instilled through a polyethylene catheter sutured into the wound at closure. If possible, instillation should be postponed until the patient has fully recovered from the effects of anaesthesia and muscle-relaxing drugs.
Monitoring
The renal function status should be evaluated by measuring the serum creatinine concentration or preferably by estimation of creatinine clearance. Blood urea nitrogen (BUN) is far less reliable for this purpose. Assessment of renal function should be performed at the start of therapy and should be re-evaluated at regular intervals during treatment.
Amikacin concentrations in serum should be measured in all patients receiving parenteral amikacin and must be measured in obesity, if high doses are being given, the elderly and in cystic fibrosis. Both peak and trough serum concentrations should be measured intermittently during therapy to ensure adequate but not excessive serum levels. In patients receiving multiple daily dosing peak concentrations (30-90 minutes after injection) of above 35μg/ml and trough concentrations (just before the next dose) of above 10μg/ml should be avoided.
In patients receiving once daily (or extended interval) dosing pre-dose ('trough') concentration should be less than 5 mcg/ml. Peak concentrations (approximately 60 minutes after administration) may exceed 35 mcg/ml.
If the pre-dose ('trough') concentration is high, the interval between doses must be increased. If the post-dose ('peak') concentration is high, the dose must be decreased.
Auditory and vestibular function should also be monitored during treatment, in particular if longer treatment duration (>7-10 days) is considered.
\*Treatment Control\*
Serum amikacin concentrations should be monitored to ensure therapeutic, but not excessively high, levels. It is recommended that serum samples be taken on the second day of treatment and then regularly, 2-3 times a week, during treatment. Trough values (just before the next dosing session) should not exceed 10 micrograms/ml. A progressive increase in the trough value reveals an ongoing accumulation, in which case the dosing interval should be extended.
Amikacin, like other aminoglycosides, is potentially nephrotoxic and ototoxic. Renal function, hearing and balance should, if possible, be checked regularly during amikacin treatment. It is extremely important to follow the dosage recommendations and to keep the patient well hydrated.
Method of administration
\*Intramuscular use or intravenous use after dilution\*.
The solution for intravenous use is prepared by adding the desired dose to 100ml or 200ml of sterile diluent such as normal saline or 5% dextrose in water or any other compatible solution. The solution is administered to adults over a 30 to 60-minute period.
In paediatric patients the amount of diluents used will depend on the amount of amikacin tolerated by the patient. The solution should normally be infused over a 30 to 60-minute period. Infants should receive a 1 to 2-hour infusion.
Amikacin should not be physically premixed with other drugs, but should be administered separately according to the recommended dose and route.
For the dilution of Amikacin see section 6.6.
Other routes of administration
Amikacin in concentrations of 0.25% (2.5 mg/ml) may be used satisfactorily as an irrigating solution in abscess cavities, the pleural space, the peritoneum and the cerebral ventricles.4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Due to the known cross sensitivities, previous hypersensitivity reactions or serious toxic reactions with any aminoglycosides may be a contraindication for the use of other aminoglycosides.
• Because of its sulphite content, Amikacin must not be used in asthmatics with sulphite hypersensitivity.4.4 Special warnings and precautions for use
\*\*Allergic reactions\*\*
Amikacin contains sodium metabisulfite which may cause severe hypersensitivity reactions in susceptible individuals, including anaphylactic symptoms and life-threatening bronchial spasms (bronchospasm). Sulfite sensitivity is generally uncommon and more frequent in asthmatics than in non-asthmatics.
Caution should be applied to patients with existing renal insufficiency, or with existing auditory or vestibular damage. Patients treated with parenteral aminoglycosides should be under close clinical observation due to potential ototoxicity and nephrotoxicity associated with treatment. The safety of treatment for longer than 14 days has not been established.
\*\*Neuro/Ototoxicity\*\*
Neurotoxicity manifesting as vestibular and/or bilateral auditory ototoxicity may occur in patients treated with aminoglycosides. The risk of aminoglycoside-induced ototoxicity is greater in patients with impaired renal function or in those where the duration of treatment is extended beyond 5-7 days, even in healthy patients. Often, deafness at high frequencies appears first and can only be detected by audiometric testing. Dizziness may occur and may be evidence of vestibular damage. Other signs of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. Patients who develop cochlear or vestibular damage do not need to have symptoms during treatment that alert them of eighth cranial nerve damage. Total or partially irreversible bilateral deafness or disabling vertigo may occur after discontinuation of the drug.
Aminoglycoside Induced ototoxicity is usually irreversible.
There is an increased risk of ototoxicity in patients with mitochondrial DNA mutations (particularly the nucleotide 1555 A to G substitution in the 12S rRNA gene), even if aminoglycoside serum levels are within the recommended range during treatment. Alternative treatment options should be considered in such patients.
In patients with a family history of relevant mutations or aminoglycoside induced deafness, alternative treatments or genetic testing prior to administration, should be considered.
\*\*Neuromuscular toxicity\*\*
Neuromuscular blockade and respiratory paralysis have been reported following parenteral injection, topical installation (as in orthopaedic flushing and abdominal lavage, or with local empyema treatment) and after oral administration of aminoglycosides. The risk of respiratory paralysis when administering aminoglycosides irrespective of the route of administration should be considered, especially in patients receiving anesthetics or neuromuscular blockers (see section 4.5 Interactions with other medications and other forms of interaction "). If neuromuscular blockade occurs, calcium salts may relieve respiratory paralysis but mechanical ventilation may be necessary.
In animal studies, neuromuscular blockade and muscular paralysis have been reported after administration of high doses of amikacin.
Aminoglycosides should be used with caution in patients with muscular disorders such as myasthenia gravis or parkinsonism as these drugs may aggravate muscle weakness due to their potential curare-like effect on the neuromuscular junction.
\*Renal toxicity:\*
Aminoglycosides are potentially nephrotoxic. Renal toxicity appears independent of plasma obtained at the peak (Cmax). The risk of nephrotoxicity is increased in patients with impaired renal function and in patients receiving high doses or prolonged treatment.
Patients should be well hydrated during treatment and renal function should be assessed by the usual methods prior to starting therapy and daily during the course of treatment. A reduction of dosage is required if evidence of renal dysfunction occurs, such as presence of urinary casts, white or red cells, albuminuria, decreased creatinine clearance, decreased urine specific gravity, increased BUN, serum creatinine, or oliguria. If azotemia increases, or if a progressive decrease in urinary output occurs, treatment should be stopped.
Elderly patients may have reduced renal function which may not be seen in the routine screening tests such as BUN (blood urea nitrogen) or serum creatinine. A creatinine clearance determination may be more helpful. Monitoring of renal function in elderly patients during treatment with aminoglycosides is particularly important.
Renal function and function of the eighth cranial nerve should be closely monitored, especially in patients with known or suspected renal impairment at the onset of treatment and also in those whose renal function is initially normal but who develop signs of renal impairment during treatment.
Serum concentrations of amikacin should be monitored (when possible) to ensure adequate levels and to avoid potential toxic levels. The urine should be examined for decreased density, increased excretion of proteins and the presence of cells or casts. BUN (blood urea nitrogen), serum creatinine, or creatinine clearance should be measured periodically. Repeat audiograms should be performed (if possible), especially in high-risk patients. Evidence of ototoxicity (dizziness, tinnitus, ringing in the ears and hearing loss) or nephrotoxicity require discontinuation of the drug or dose adjustment.
Concomitant and/or sequential systemic, oral, or topical use of other neurotoxic or nephrotoxic products, particularly bacitracin, cisplatin, amphotericin B, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides, should be avoided. Other factors that may increase risk of toxicity are advanced age and dehydration.
Inactivation of aminoglycosides is clinically significant only in patients with severe renal impairment. Inactivation may persist in body fluid samples collected for analysis, resulting in incorrect aminoglycoside readings. Such samples should be handled properly (analyzed immediately, frozen, or treated with beta-lactamase).
Diarrhoea/pseudomembranous colitis caused by \*Clostridium difficile\* occurs. Patients with diarrhoea must therefore be monitored closely.
\*\*Other\*\*
Aminoglycosides are quickly and almost totally absorbed when they are applied topically, except to the urinary bladder, in association with surgical procedures. Irreversible deafness, renal failure and death due to neuromuscular blockade have been reported following irrigation of both small and large surgical fields with an aminoglycoside preparation.
Prolonged antibiotic use may occasionally lead to overgrowth of resistant pathogens. The patient should be constantly monitored in this regard. Should a superinfection occur during therapy, appropriate measures must be taken.
Macular infarction sometimes leading to permanent loss of vision has been reported following intravitreous administration (injection into the eye) of amikacin.
\*\*Paediatric use\*\*
Aminoglycosides should be used with caution in premature and neonatal infants because of the renal immaturity of these patients and the resulting prolongation of serum half-life of these drugs.
\*\*Amikacin contains sodium\*\*
2 ml vial
This medicine contains less than 1 mmol sodium (23mg) per 2ml vial, that is to say essentially 'sodium-free'.
4 ml vial
This medicinal product contains 26.65 mg sodium per 4ml vial, equivalent to 1.33% of the WHO recommended maximum daily intake of 2g sodium for an adult.4.5 Interaction with other medicinal products and other forms of interaction
Concomitant or repeated use of other neurotoxic, ototoxic or nephrotoxic agents, particularly bacitracin, cisplatin, amphotericin B, cyclosporine, tacrolimus, cephaloridine, paromomycin, viomycin, polymyxin B, colistimethate/colistin, vancomycin, or other aminoglycosides should be avoided regardless of systemic or local administration due to the risk of additive effects. Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins. Concomitant treatment with a cephalosporin may result in falsely elevated creatinine serum level determinations.
The risk of ototoxicity is increased when amikacin is used in conjunction with rapidly acting diuretic drugs, particularly when the diuretic is administered intravenously. Diuretics may enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. Such agents include furosemide and ethacrynic acid which is itself an ototoxic agent. Irreversible deafness may result.
A reduction in serum activity of aminoglycosides may occur with concomitant use of penicillin-type drugs.
There is an increased risk of hypocalcaemia when aminoglycosides are administered with bisphosphonates.
There is an increased risk of nephrotoxicity and possibly of ototoxicity when aminoglycosides are administered with platinum compounds.
Concomitantly administered thiamine (vitamin B1) may be destroyed by the reactive sodium metabisulfite component of the amikacin sulfate formulation.
Indomethacin may increase the plasma concentration of amikacin in neonates.
In patients receiving anaesthetics or muscle-relaxing agents (such as d-tubocurarine, succinylcholine, decamethonium, atracurium, rocuronium, vecuronium) or in patients receiving massive transfusions of citrate-anticoagulated blood) as neuromuscular blockade and consequent respiratory depression may occur.
Some antibiotics could, in rare cases, reduce the effectiveness of oral contraceptives by interfering with the bacterial hydrolysis of steroid conjugates in the gut and thus the reabsorption of unconjugated steroid. Thereby, the plasma levels of active steroid would decrease. This unusual interaction would occur in women with high biliary excretion of steroid conjugates. This interaction has not been reported for amikacin.4.6 Fertility, pregnancy and lactation
Pregnancy
Amikacin should be used in pregnant women and newborns only if clearly indicated and under medical supervision (see section 4.4).
There is limited data on the use of aminoglycosides in pregnancy.
Aminoglycosides can affect the development of the embryo / foetus in the womb. Aminoglycosides cross the placental barrier and there have been reports of total, irreversible, bilateral congenital deafness in children whose mothers were treated with streptomycin during pregnancy.
Although adverse reactions to the foetus or neonate in pregnant women who have been treated with other aminoglycosides have not been reported, there is potential for harm.
If amikacin is used during pregnancy or if the patient becomes pregnant during treatment with this drug, the patient should be informed of the possible risks to the foetus.
Breast-feeding
It is not known if amikacin passes into the breast milk. The decision should be made to either stop breastfeeding or stop the treatment.
Fertility
In reproduction toxicity studies in mice and rats, no effects on fertility or foetal toxicity were reported.4.7 Effects on ability to drive and use machines
No studies on the ability to drive and the use of machines have been performed. However, the occurrence of some side effects (see section 4.8) may impair the ability to drive vehicles and operate machinery.4.8 Undesirable effects
All aminoglycosides can induce ototoxicity, renal toxicity and neuromuscular blockade. The risk of these toxicities is greater in patients with impaired renal function, in patients receiving more than the recommended dose, prolonged treatment and in patients treated with other ototoxic or nephrotoxic drugs (see section 4.4 "Special warnings and precautions for use").
The frequency of the side effects listed below is defined using the following conventions:
very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (frequency cannot be estimated from the available data).
The frequency of the adverse reactions listed below is defined by the following groupings:
| | | |
| --- | --- | --- |
| \*\*MedDRA system organ class\*\* | \*\*Frequency\*\* | \*\*Adverse event\*\* |
| Infections and Infestations | Uncommon | Super infection or colonization with resistant bacteria or yeasts a. |
| Blood and lymphatic system disorders | Rare | Anaemia, eosinophilia, granulocytopenia, leukopenia, thrombocytopenia |
| Immune system disorders | Not known | Anaphylactic response (anaphylactic reaction, anaphylactic shock and anaphylactoid reaction), hypersensitivity |
| Metabolism and nutrition disorders | Rare | Hypomagnesemia |
| Nervous system disorders | Common | Dizziness |
| Rare | Tremor a, paraesthesiaa, headache, balance disorders |
| Not known | Acute muscular paralysisa |
| Eye disorders | Rare | Blindnessb, retinal infarctionb |
| Ear and labyrinth disorders | Common | Vestibular disorders with nausea |
| Rare | Tinnitusa, hearing lossa |
| Not known | Deafness a, neurosensory deafness a |
| Cardiovascular | Rare | Hypotension, hypotonia, thrombophlebitis tachycardia, myocarditis |
| Respiratory, thoracic and mediastinal disorders | Not known | Apnoea, bronchospasm |
| Gastrointestinal disorders | Uncommon | Vomiting, nausea |
| Hepatobiliary disorders | Uncommon | Elevation of liver enzymes in plasma (SGOT, SGPT, LDH, alkaline phosphatase and bilirubin) |
| Skin and subcutaneous tissue disorders | Uncommon | Rash |
| Rare | Pruritus, urticaria |
| Musculoskeletal and connective tissue disorders | Rare | Arthralgia, muscle contractionsa |
| Renal and urinary disorders | Common | Proteinuria, urea increase |
| Rare | Oliguriaa, serum creatinine increasea, albuminuriaa, azotemiaa, presence of red and white blood cells in the urinea |
| Not known | acute renal failure, toxic nephropathy, cells in the urinea |
| General disorders and administration site conditions | Rare | Fever |
| Not known | Pain in the injection site |
a. See section 4.4 "Special warnings and precautions for use"
b. Amikacin is not formulated for intravitreal use. Blindness and retinal infarction have been reported following intravitreal administration (injection into the eye) of amikacin.
Description of selected adverse reactions
Cases of skin and mucosal reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported, however with an unclear connection.
\*Kidney and urinary tract disorders\*
Nephrotoxicity is manifested as increased excretion of tubule epithelia, cylindruria, increase in β2-microglobulin excretion, enzyme excretion via urine (e.g. alanine aminopeptidase, glutamine transferase, β-galactosidase, N-acetyl-glucosaminidase), azotemia, decrease in urine osmolarity, increase in blood urea nitrogen and serum creatinine, decrease in creatinine clearance. In case of minor irritations (albumin, erythrocytes, leukocytes or cylinders in urine) the fluid intake should be increased. After discontinuation of the drug, renal impairment is usually reversible.
As with all aminoglycosides, there have been reports of nephrotoxicity and acute renal failure following approval of amikacin.
\*Disorders of the ear and the labyrinth\*
Ototoxic reactions involving the 8th cranial nerve occur in approximately 0.5 - 5% of the treated patients. This may involve vestibular or cochlear function (see section 4.4 "Special warnings and precautions for use").
When treating with amikacin, special attention should be paid to cochlear damage. These are manifested as tinnitus, pressure in the ears and initially merely as audiometrically detectable decrease of acoustic perceptions in the high frequency range (> 4000 Hertz) above the speech range. However, hearing loss can develop to complete, irreversible deafness despite discontinuation of the aminoglycoside. Vestibular disorders manifest in initial symptoms such as dizziness, nausea, and vomiting. In the clinical examination usually a nystagmus is detected. At the first sign of hearing or balance disorders, amikacin therapy should be discontinued.
\*Disorder of the nervous system\*
\*Neuromuscular blockades:\*
Specific risks are very rare when taking aminoglycosides. The occurrence of neuromuscular blockade, which can lead to respiratory arrest, can occur especially with intrapleural or intraperitoneal administration. The neuromuscular blocking properties of the aminoglycosides are enhanced by inhalation narcotics or muscle relaxants or curare-like drugs. Particularly at risk are patients with myasthenia gravis. Respiratory paresis requires artificial respiration. In addition, the application of potassium salts may be considered as a countermeasure.
\*Immune system disorders\*
Due to the content of sulfite it can lead to hypersensitivity reactions that may manifest as vomiting, diarrhea, wheezing, acute asthma attack, disturbance of consciousness or shock in individual cases, especially in bronchial asthma. These reactions can vary widely individually and can lead to life-threatening conditions
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
In case of overdose, there is a significant risk of nephro, oto- and neurotoxic (neuromuscular blockade) reactions. Respiratory neuromuscular blockade should be immediately treated, including the administration of calcium in ionised form (for example as gluconate or lactobionate in 10-20% solution) (see section 4.4 "Special warnings and precautions for use"). In cases of overdose or toxic reactions, amikacin can be removed from the blood by peritoneal or haemodialysis. Continuous arteriovenous haemofiltration also leads to a reduction of amikacin. In neonates, an exchange transfusion may be considered.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antibiotics for systemic use, aminoglycoside antibiotics, ATC code: J01GB06.
Amikacin is a kanamycin-derived semisynthetic aminoglycoside antibiotic which works by stopping the bacteria's protein synthesis. The substance has a bactericidal effect.
Mechanism of action
The mechanism of action of amikacin is due to a disruption of protein biosynthesis on the bacterial ribosome by interaction with the rRNA and subsequent inhibition of translation. This results in a bactericidal effect.
\*Relationship between pharmacokinetics and pharmacodynamics\*
The efficacy depends essentially on the quotient of maximum serum concentration (Cmax) and minimal inhibitory concentration (MIC) of the pathogen.
\*Resistance mechanisms\*
Resistance to amikacin may be due to the following mechanisms:
• Enzymatic Inactivation: Enzymatic modification of aminoglycoside molecules is the most common mechanism of resistance. Acetyltransferases, phosphotransferases or nucleotidyltransferases are responsible for this, most of which are plasmid-encoded. Amikacin is highly stable to aminoglycoside-inactivating enzymes. It can therefore inhibit bacteria that are resistant to gentamicin and other aminoglycosides.
• Reduced penetration and active efflux: These resistance mechanisms are mainly found in \*Pseudomonas aeruginosa\*.
• Alteration of the target structure: Modifications within the ribosomes are the cause of resistance.
There is partial cross-resistance of amikacin with other aminoglycoside antibiotics.
\*Threshold values\*
The assay of amikacin is carried out using usual serial dilution. The following minimum inhibitory concentrations for sensitive and resistant pathogens have been established:
EUCAST Clinical MIC Breakpoints for amikacin (EUCAST Clinical Breakpoint table version 13.0, valid from 01-01-2023).
| | |
| --- | --- |
| \*\*Pathogen\*\* | \*\*Species-related breakpoints, mg / L of amikacin\*\* \*\*(S ≤ / R >)\*\* |
| \*Enterobacterales\* (systemic infections) | 8/81 |
| \*Enterobacterales\* (infections originating from the urinary tract) | 8/8 |
| \*Pseudomonas\* spp. (systemic infections) | 16/161 |
| \*Pseudomonas\* spp. (infections originating from the urinary tract) | 16/16 |
| \*Acinetobacter\* spp. (systemic infections) | 8/81 |
| \*Acinetobacter\* spp. (infections originating from the urinary tract) | 8/8 |
| \*Staphylococcus\* spp. (\*S.aureus\*) | 16/161 |
| \*Staphylococcus\* spp. (coagulase-negative staphylococci | 16/16 |
| \*Enterococcus spp.\* | Note2/ Note2 |
| \*Viridans group streptococci\* | Note2/ Note2 |
| \*Haemophilus influenzae\* | IE/IE |
| \*Moraxella catarrhalis\* | IE/IE |
| PK-PD (Non-species related) breakpoints | 1/1 |
1 For systemic infections, aminoglycosides should be used in combination with other active therapy. In this circumstance, the value in brackets can be used to distinguish between wild type organisms and organisms with acquired resistance mechanisms.
Note2 - Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
IE- Insufficient evidence
The prevalence of acquired resistance of individual species may vary over place and over time. Therefore, local information about the resistance situation is required, especially for the adequate treatment of severe infections. If the efficacy of amikacin is questionable due to the local resistance situation, expert therapy counselling should be sought. Particularly in the case of severe infections or treatment failures, a microbiological diagnosis with detection of the pathogen and its sensitivity to amikacin should be sought.
| |
| --- |
| \*\*Sensitive Species\*\* \*\*Aerobic gram-positive micro-organisms\*\* Staphylococcus aureus Staphylococcus haemolyticus Staphylococcus hominis \*\*Aerobic gram-negative micro-organisms\*\* Coagulase negative staphylococci Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzae Klebsiella oxytoca Klebsiella pneumoniae Morganella morganii Proteus mirabilis Proteus vulgaris Providencia Pseudomonas aeruginosa 1) Salmonella enterica (enteritis salmonella) Serratia liquefaciens ° Serratia marcescens Shigella spp. \*\*Species in which acquired resistance can be a problem\*\* \*\*Aerobic gram-positive micro-organisms\*\* Staphylococcus epidermis \*\*Aerobic gram-negative micro-organisms\*\* Acinetobacter baumannii \*\*Naturally resistant species\*\* \*\*Aerobic gram-positive micro-organisms\*\* Enterococcus spp. Streptococcus spp. Pneumococcus \*\*Aerobic gram-negative micro-organisms\*\* Burkholderia cepacia Stenotrophomonas maltophilia Meningococcus \*\*Anaerobic micro-organisms\*\* Bacteroides spp. Prevotella spp. Clostridium difficile Legionella \*\*Other micro-organisms\*\* Chlamydia spp. Chlamydophila spp. Mycoplasma spp. Urea plasma urealyticum |
oThere were no latest data when the tables were published. The primary literature, standard works and therapy recommendations presume sensitivity.
1) For isolates of particular patient groups, e.g. Patients with cystic fibrosis, the resistance rate ≥10%.
Resistance occurs (1-10%) in Pseudomonas aeruginosa and is common (>10%) in coagulase-negative staphylococci.
In combination with a beta-lactam antibiotic, a synergistic effect is often achieved against most bacteria including streptococci and enterococci.5.2 Pharmacokinetic properties
Amikacin is rapidly absorbed after intramuscular administration. Doses of 250 mg and 500 mg intramuscularly give maximum serum concentrations of approximately 12 micrograms/ml and approximately 21 micrograms/ml after one hour, respectively. After 10 hours, the serum concentration is approximately 0.3 micrograms/ml and approximately 2.1 micrograms/ml, respectively.
In intravenous infusion of 500 mg (7.5 mg/kg) over 30 minutes, a maximum serum concentration of an average of 38 micrograms/ml is obtained immediately after the infusion and 30 minutes after the end of the infusion a concentration of 24 micrograms/ml. In the case of infusion of 15 mg/kg, the corresponding concentrations are 77 micrograms/ml and 47 micrograms/ml, respectively.
Plasma protein binding of amikacin is low and ranges from 0-11%. The volume of distribution is about 24 liters in an adult or about 28% of body weight. Amikacin rapidly distributes itself to different tissues after parenteral administration. Amikacin passes into the cerebrospinal fluid in small amounts in intact meninges, while the blood- CSF barrier is penetrated more easily in meningitis. There is no accumulation with repeated dosing.
Amikacin is not metabolized and is excreted in active form almost exclusively by glomerular filtration. In normal renal function, the half-life is about 2 hours and 92% of a given dose is excreted unchanged in the urine within 8 hours and 98% within 24 hours.
In case of impaired renal function, excretion is significantly delayed.
Data from trials with multiple daily doses show that levels in cerebrospinal fluid in normal children are about 10-20% of the serum concentration and may reach up to 50% in meningitis.
\*Intramuscular and intravenous administration:\*
Renal elimination of amikacin is reduced in newborns and especially in premature infants.
\*Experiences in children\*
Data from dosing studies on a daily basis show that levels in CSF in normal children are around 10 to 20% of serum concentrations and may reach 50% in meningitis.
The elimination of amikacin was reduced in newborns and especially in preterm infants.
In a study of newborns (aged 1-6 days old) children were grouped by birth weight (<2000 g, 2000-3000 g and > 3000 g). Amikacin was given intramuscularly and/or intravenously at a dose of 7.5mg/kg. The neonatal clearance > 3000g was 0.84 ml/min/kg and the terminal half-life was about 7 hours. In this group, the initial volume of distribution was 0.3 ml/kg and the volume of distribution at steady state was 0.5 ml/kg. In the lower birth weight groups, the clearance/kg was lower and the half-life longer. Repeated dosing every 12 hours in all the specified groups showed no accumulation after 5 days.5.3 Preclinical safety data
No long-term studies have been performed to evaluate the carcinogenic or mutagenic potential. Studies in rats have shown that daily doses up to 10 times recommended dose for humans did not cause any adverse effects on male and female fertility.
Neuromuscular blockade has been seen in laboratory animals after high doses (see section 4.4).
## Pharmaceutical Particulars
6.1 List of excipients
Sodium metabisulfite (E223)
Sodium citrate dihydrate
Sulfuric acid
Water for injection6.2 Incompatibilities
Aminoglycosides such as amikacin should not be combined with other medicines, but must be administered separately. Aminoglycosides and penicillins can inactivate each other \*in vitro\*, with loss of antibacterial activity.6.3 Shelf life
2 years
Intended for single use. Residual quantities are to be discarded.
After dilution:
Chemical and physical in use stability has been demonstrated for 36 hours at 25°C, 30 days at -15°C and 60 days at 4°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.6.5 Nature and contents of container
Amikacin 500mg/2ml (250mg/ml) is available as a clear, colourless to light straw-coloured solution, packed in a 2ml clear Type-I glass vial with a dark grey, chlorobutyl rubber stopper and a flip off seal.
2 ml (500 mg): 1 and 5 vials
Amikacin 1g/4ml (250mg/ml) is available as a clear, colourless to light straw-coloured, solution, packed in a 5ml clear Type-I glass vial with a dark grey, chlorobutyl rubber stopper and a flip off seal.
4 ml (1,000 mg): 1 and 5 vials
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
No special requirements for disposal.
Like all parenterals, Amikacin should be checked for particulate matter and discoloration before use. Only clear solutions which, at most, are slightly yellow in colour should be used. A pale yellow solution is not an indicator of reduced efficacy.
For intravenous infusion, Amikacin is given at the calculated dose in 100ml or 200ml of sterile infusion solution. The solution is administered to adults in a 30-60 minute infusion. For dosing in adults and children see section 4.2 "Posology and method of administration".
Suitable solvents for intravenous infusion are:
0.9% NaCl solution for infusion
5% glucose solution for infusion
Ringer's lactate solution without 5% glucose
